Table 3 Summary of the literature review on the toxicity profile of pembrolizumab
Keynote-042 [9] % | Keynote-024 [8] % | Real-world study % | |
|---|---|---|---|
Cutaneous Toxicities | 14.0 | 22.1 | 30.1 (p = 0.0008) |
Endocrinological Toxicities | 17.0 | 17.5 | 20.4 (p = 0.0005) |
Gastrointestinal Toxicities | 13 | 32 | 27.5 (p = 0.5) |
Overall Toxicities | 63 | 76.6 | 77.5 (p = 0.006) |